S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
High oil prices help Saudi Aramco earn $88B in first half
Apple’s Next “Star Product” Could Replace The iPhone? (Ad)pixel
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Germans urged to cap heat in offices this winter to save gas
Former Deutsche Bank Co-CEO Anshu Jain dies
US Dollar Replaced By "Biden Bucks"? (Ad)
NASDAQ:CLRB

Cellectar Biosciences - CLRB Stock Forecast, Price & News

$5.88
+0.03 (+0.51%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.70
$5.99
50-Day Range
$3.57
$6.23
52-Week Range
$3.37
$10.90
Volume
40,508 shs
Average Volume
47,107 shs
Market Capitalization
$35.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.25

Cellectar Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
452.7% Upside
$32.50 Price Target
Short Interest
Healthy
0.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Cellectar Biosciences in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.21) to ($3.24) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

859th out of 1,135 stocks

Pharmaceutical Preparations Industry

436th out of 557 stocks

CLRB stock logo

About Cellectar Biosciences (NASDAQ:CLRB) Stock

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cellectar Biosciences Price Performance

Shares of NASDAQ:CLRB traded up $0.03 during trading on Friday, reaching $5.88. 40,508 shares of the company were exchanged, compared to its average volume of 47,107. Cellectar Biosciences has a 12-month low of $3.37 and a 12-month high of $10.90. The firm has a market capitalization of $35.93 million, a PE ratio of -1.39 and a beta of 1.42. The business's fifty day simple moving average is $4.43 and its 200-day simple moving average is $5.02.

Cellectar Biosciences (NASDAQ:CLRB - Get Rating) last released its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($1.00) EPS for the quarter, topping analysts' consensus estimates of ($1.10) by $0.10. On average, sell-side analysts anticipate that Cellectar Biosciences will post -4.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on CLRB. Maxim Group dropped their price target on shares of Cellectar Biosciences to $12.50 in a research note on Thursday, May 26th. StockNews.com started coverage on Cellectar Biosciences in a research note on Tuesday. They set a "sell" rating for the company. Finally, Oppenheimer reiterated an "outperform" rating and issued a $55.00 target price on shares of Cellectar Biosciences in a research note on Monday, July 18th.

Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLRB Stock News Headlines

Cellectar Dips on Q2 Figures
Cellectar Announces Stock Consolidation
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences GAAP EPS of -$0.10 in-line
Recap: Cellectar Biosciences Q4 Earnings
See More Headlines
Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLRB Company Calendar

Last Earnings
11/07/2021
Today
8/14/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLRB
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$32.50
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$12.50
Forecasted Upside/Downside
+261.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-24,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.08 per share

Miscellaneous

Free Float
5,939,000
Market Cap
$35.93 million
Optionable
Not Optionable
Beta
1.42

Key Executives

  • Mr. James V. Caruso (Age 63)
    Pres, CEO & Director
    Comp: $679.25k
  • Mr. Jarrod Longcor (Age 49)
    Chief Operating Officer
    Comp: $477.45k
  • Mr. Chad J. Kolean CPA (Age 58)
    CPA, CFO & Sec.
  • Dr. Laurence Reilly L.L.M.
    LL.M, M.D., MBChB, Interim Chief Medical Officer













CLRB Stock - Frequently Asked Questions

Should I buy or sell Cellectar Biosciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLRB shares.
View CLRB analyst ratings
or view top-rated stocks.

What is Cellectar Biosciences' stock price forecast for 2022?

2 brokerages have issued twelve-month target prices for Cellectar Biosciences' stock. Their CLRB share price forecasts range from $12.50 to $55.00. On average, they predict the company's share price to reach $32.50 in the next twelve months. This suggests a possible upside of 452.7% from the stock's current price.
View analysts price targets for CLRB
or view top-rated stocks among Wall Street analysts.

How have CLRB shares performed in 2022?

Cellectar Biosciences' stock was trading at $6.64 at the beginning of the year. Since then, CLRB stock has decreased by 11.4% and is now trading at $5.88.
View the best growth stocks for 2022 here
.

When is Cellectar Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our CLRB earnings forecast
.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) posted its quarterly earnings results on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.10.

When did Cellectar Biosciences' stock split?

Shares of Cellectar Biosciences reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.73%) and Franklin Resources Inc. (1.70%). Insiders that own company stock include Dov Elefant, James V Caruso, Jarrod Longcor and Stephen A Hill.
View institutional ownership trends
.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $5.88.

How much money does Cellectar Biosciences make?

Cellectar Biosciences (NASDAQ:CLRB) has a market capitalization of $35.93 million. The biopharmaceutical company earns $-24,120,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The official website for the company is www.cellectar.com. The biopharmaceutical company can be reached via phone at (608) 441-8120, via email at ir@cellectar.com, or via fax at 608-441-8121.

This page (NASDAQ:CLRB) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.